{"id":113799,"date":"2021-05-07T13:06:33","date_gmt":"2021-05-07T13:06:33","guid":{"rendered":"https:\/\/fin2me.com\/?p=113799"},"modified":"2021-05-07T13:06:33","modified_gmt":"2021-05-07T13:06:33","slug":"canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/","title":{"rendered":"Canada says it's ready to discuss COVID-19 vaccine IP waiver"},"content":{"rendered":"
Healthcare workers prepare doses of the Pfizer\/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, at Woodbine Racetrack pop-up vaccine clinic in Toronto, Ontario, Canada May 5, 2021. REUTERS\/Carlos Osorio<\/figcaption>

OTTAWA (Reuters) -Canada said on Friday it was prepared to discuss an intellectual property rights (IP) waiver for COVID-19 vaccines while also stressing the importance of protecting IP and the integral role industry played in developing the medicines.<\/p>\n

U.S. President Joe Biden on Wednesday threw his support behind waiving IP rights for COVID-19 vaccines. Any such waiver would have to be negotiated through the World Trade Organization (WTO).<\/p>\n

\u201cCanada is ready to discuss proposals on a waiver for intellectual property protection, particular to COVID-19 vaccines, under the WTO Agreement on TRIPS,\u201d said International Trade Minister Mary Ng, referring to the WTO\u2019s agreement on Trade-Related Aspects of Intellectual Property Rights.<\/p>\n

\u201cSince the introduction of the IP waiver proposal, Canada has actively worked with partners to identify barriers to vaccine access \u2014 many of which are unrelated to IP, such as supply chain constraints,\u201d she said in a statement.<\/p>\n

Biden\u2019s proposal angered pharmaceutical companies. Firms working on vaccines have reported sharp revenue and profit gains during the crisis.<\/p>\n

Ng also stressed that \u201cour government firmly believes in the importance of protecting IP and recognizes the integral role that industry has played in innovating to develop and deliver life-saving COVID-19 vaccines.\u201d<\/p>\n

Source: Read Full Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Healthcare workers prepare doses of the Pfizer\/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, […]<\/p>\n","protected":false},"author":3,"featured_media":113798,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"yoast_head":"\nCanada says it's ready to discuss COVID-19 vaccine IP waiver - Fin2me<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Canada says it's ready to discuss COVID-19 vaccine IP waiver - Fin2me\" \/>\n<meta property=\"og:description\" content=\"Healthcare workers prepare doses of the Pfizer\/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/\" \/>\n<meta property=\"og:site_name\" content=\"Fin2me\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-07T13:06:33+00:00\" \/>\n<meta name=\"author\" content=\"Mark\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/05\/Canada-says-its-ready-to-discuss-COVID-19-vaccine-IP-waiver.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/\",\"url\":\"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/\",\"name\":\"Canada says it's ready to discuss COVID-19 vaccine IP waiver - Fin2me\",\"isPartOf\":{\"@id\":\"https:\/\/fin2me.com\/#website\"},\"datePublished\":\"2021-05-07T13:06:33+00:00\",\"dateModified\":\"2021-05-07T13:06:33+00:00\",\"author\":{\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\"},\"breadcrumb\":{\"@id\":\"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fin2me.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Markets\",\"item\":\"https:\/\/fin2me.com\/category\/markets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Canada says it's ready to discuss COVID-19 vaccine IP waiver\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fin2me.com\/#website\",\"url\":\"https:\/\/fin2me.com\/\",\"name\":\"Fin2me\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fin2me.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\",\"name\":\"Mark\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"caption\":\"Mark\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Canada says it's ready to discuss COVID-19 vaccine IP waiver - Fin2me","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/","og_locale":"en_US","og_type":"article","og_title":"Canada says it's ready to discuss COVID-19 vaccine IP waiver - Fin2me","og_description":"Healthcare workers prepare doses of the Pfizer\/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, [...]","og_url":"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/","og_site_name":"Fin2me","article_published_time":"2021-05-07T13:06:33+00:00","author":"Mark","twitter_card":"summary_large_image","twitter_image":"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/05\/Canada-says-its-ready-to-discuss-COVID-19-vaccine-IP-waiver.jpg","twitter_misc":{"Written by":"Mark","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/","url":"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/","name":"Canada says it's ready to discuss COVID-19 vaccine IP waiver - Fin2me","isPartOf":{"@id":"https:\/\/fin2me.com\/#website"},"datePublished":"2021-05-07T13:06:33+00:00","dateModified":"2021-05-07T13:06:33+00:00","author":{"@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a"},"breadcrumb":{"@id":"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fin2me.com\/markets\/canada-says-its-ready-to-discuss-covid-19-vaccine-ip-waiver\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fin2me.com\/"},{"@type":"ListItem","position":2,"name":"Markets","item":"https:\/\/fin2me.com\/category\/markets\/"},{"@type":"ListItem","position":3,"name":"Canada says it's ready to discuss COVID-19 vaccine IP waiver"}]},{"@type":"WebSite","@id":"https:\/\/fin2me.com\/#website","url":"https:\/\/fin2me.com\/","name":"Fin2me","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fin2me.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a","name":"Mark","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fin2me.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","caption":"Mark"}}]}},"_links":{"self":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/113799"}],"collection":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/comments?post=113799"}],"version-history":[{"count":0,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/113799\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media\/113798"}],"wp:attachment":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media?parent=113799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/categories?post=113799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/tags?post=113799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}